Nephrology
Nephrolithiasis
22
Pipeline Programs↗
3
Active Trials↗
15
Companies Involved↗
Nephrolithiasis is an emerging landscape with 22 programs across 15 companies. The most active players are Javelin Pharmaceuticals, AbbVie, Validus Pharmaceuticals. 13 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 1
No programs
Phase 2
No programs
Analysis
Trial Status
8
clinical trials
Completed3 · 38%
Recruiting2 · 25%
Unknown status1 · 13%
Not yet recruiting1 · 13%
Terminated1 · 13%
Clinical Trials
Trial Activity
8 trials
Prediction of Recurrence and Complications of Nephrolithiasis Using a Precision Medicine Approach
Recruiting·—·N/A·NCT05237063·2,000 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)